Distalmotion told MedTech Dive on April 29 that its DEXTER robotic surgery system has now been used in more than 3,000 procedures across Europe and the U.S., that Q1 2026 was the company’s strongest quarter to date, and that its first U.S. ambulatory surgery center installation went live in Wichita in March. The pitch is that surgeries are leaving hospital operating rooms for ASCs faster than the legacy surgical robotics platforms can follow, and that a 125-square-foot, four-minute-setup, single-use-instrument robot is the spec that fits where the volume is going. The same week brought J&J’s definitive agreement to acquire Atraverse Medical, the launch of the PERSIGMA head-to-head trial pitting Varipulse Pro against Boston Scientific’s Farapulse, and a $150 million Series E for Aidoc’s clinical AI foundation model. Read across the four, the next phase of surgical robotics and interventional medtech is being defined by where the procedures actually happen, not by which robot ships the most instruments.
Distalmotion Crosses 3,000 Procedures and Plants the Flag in U.S. ASCs
Distalmotion CEO Greg Roche told MedTech Dive on April 29 that DEXTER has surpassed 3,000 cumulative procedures in Europe and the U.S., that Q1 2026 was the company’s best quarter, and that Cypress Surgery Center in Wichita, Kansas became the first U.S. ASC to acquire a DEXTER system in March. The platform is purpose-built for the lower-acuity site of care: a 125-square-foot footprint that fits through a standard doorway, four-minute setup, single-use instruments that eliminate sterilization workflow, and an open architecture that accepts third-party visualization and instruments. FDA de novo authorization has stacked through inguinal hernia repair in 2024, gallbladder removal and hysterectomy in 2025, and additional gynecology indications and ventral hernia repair pending. Distalmotion has raised approximately $400 million to date, including a $150 million Series G and a strategic investment from J&J’s venture arm.
The structural backdrop for the strategy is that Medicare-certified ASCs grew at an average annual rate of 2.2% over five years and now exceed 6,400 facilities, while hospital openings have lagged closures over a 14-year window through 2023. Procedural migration into the ASC channel is the largest site-of-care shift in surgery, and the surgical robotics platforms designed for hospital operating rooms struggle to meet the ASC spec on footprint, capital intensity, and sterilization economics. The Distalmotion bet is that the platform engineered for the site where volume is moving wins the next phase of competition, even as Intuitive continues to dominate the installed hospital base.
J&J Adds Atraverse to the Cardiac Ablation Stack as PFA Heads to the Same Site Shift
J&J announced a definitive agreement on April 27 to acquire Atraverse Medical, developer of the Hotwire transseptal access system, with the deal expected to close in Q2 2026 and financial terms undisclosed. The Hotwire radiofrequency guidewire received initial FDA clearance in May 2024 and has been used in nearly 3,000 procedures by close to 100 cardiac electrophysiologists and interventional cardiologists since limited launch. J&J highlighted the impedance-sensing automatic energy shutoff, multi-sheath compatibility, and intracardiac echocardiography tip visibility as the differentiators it is integrating into the broader cardiovascular portfolio. J&J’s cardiovascular unit grew 13% in Q1 2026 to $2.38 billion, driven by Abiomed and Shockwave assets that the company has been weaving into a single ablation, mapping, and access stack.
The day after the Atraverse announcement, J&J disclosed the PERSIGMA randomized trial enrolling up to 466 patients across 50 sites to compare Varipulse Pro against Boston Scientific’s Farapulse in persistent atrial fibrillation. Endpoints are seven-day adverse events and freedom from atrial tachyarrhythmia from day 61, with first cases at HRS 2026 in Chicago. Pulsed field ablation is the procedural innovation accelerating the migration of complex AFib cases out of the academic medical center and into community electrophysiology suites, and a head-to-head trial against the category leader is the evidence J&J needs to displace Farapulse from the procedural workflow that follows the site shift.
Aidoc Raises $150M for a Clinical AI Foundation Model Already Live in 2,000 Hospitals
Aidoc closed a $150 million Series E on April 29, led by Goldman Sachs Alternatives Growth Equity with participation from General Catalyst, SoftBank Vision Fund 2, and NVIDIA’s NVentures. The capital backs CARE, the company’s clinical foundation model, which received what the company described as the first FDA clearance for a comprehensive double-digit foundation-model-based triage system in clinical imaging earlier this year. CARE is deployed through the aiOS enterprise platform across nearly 2,000 hospitals and analyzes more than 60 million patient cases annually. Funding will extend additional clinical indications and add automated imaging draft report creation to the workflow.
The connection to the site-of-care frame is that clinical AI infrastructure is the only practical way to maintain consistent imaging triage and decision support across a network that spans hospital ORs, hospital outpatient departments, ASCs, and community imaging centers. A radiology read or a pre-procedural imaging triage pipeline that runs identically across the multi-site enterprise is what makes the procedural migration economically viable for the hospital systems and platform vendors operating across both sides of the shift. The Aidoc round is enterprise-scale clinical AI for the network where surgical and interventional procedures are now distributed, not concentrated.
What the Site-of-Care Shift Changes for Surgical Robotics and Interventional Founders
Three operational shifts follow from this week. The first is that the platform spec for surgical robotics is being rewritten around the ASC environment, where small footprint, fast setup, single-use instrumentation, and capital-light commercial models are gating procurement decisions that the hospital-OR generation of platforms was never designed to win. The second is that the strategic acquirers are assembling cardiovascular and electrophysiology portfolios that follow the procedural migration, and J&J’s combination of Varipulse Pro, Carto 3 mapping, the Atraverse transseptal access system, and the PERSIGMA evidence campaign is the integrated answer to where AFib cases are now being treated. The third is that the clinical AI infrastructure layer is consolidating around a small number of foundation-model platforms with the regulatory clearances and the multi-thousand-hospital deployment footprint to operate across the entire site network, and the venture-backed AI tools that do not get into that infrastructure layer will struggle to land enterprise contracts in the post-shift world.
Founders building surgical robotics platforms in 2026 should be reading the Distalmotion ASC entry as the new commercial frontier, the J&J cardiac ablation stack-build as the model for following the procedural migration into the lower-acuity site of care, and the Aidoc Series E as the signal that clinical AI infrastructure for the multi-site enterprise is now the layer the strategic acquirers and the hospital systems are paying for.
Dave’s take
The site-of-care shift is the structural change that decides which surgical robotics and interventional platforms compound through the rest of the decade, and the founders I work with should be designing for the ASC and the community electrophysiology suite from initial product architecture, not retrofitting after first hospital clearance. The platform that wins the next phase is the one that fits the room where the procedures are moving, with the workflow that the lower-acuity site can actually run, and the commercial model that matches the smaller capital budget. Build for where volume is going, not for where the legacy installed base sits today.
I’m here to help you scale.
Work With Dave